Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Abiomed Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
- Get full access to the entire website from $10.42/mo, or 
- get 1-month access to Abiomed Inc. for $22.49. 
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).
The financial data reveals a limited but consistent profile in the leverage ratios over the observed periods. The debt-related metrics were only recorded in the earlier quarters of 2017, showing a very low level of debt relative to equity, capital, and assets.
- Debt to Equity
- The ratio remained constant at 0.03 in the two reported periods, indicating minimal reliance on debt compared to shareholder equity during the first half of 2017.
- Debt to Capital
- Similarly, this ratio held steady at 0.03, reflecting a stable capital structure with debt making up a small proportion of total capital in the same timeframe.
- Debt to Assets
- The ratio was 0.02 consistently in the two available periods, underscoring low indebtedness relative to total assets, suggesting a conservative approach to financing.
- Financial Leverage
- Measured over multiple quarters from mid-2017 through late 2022, financial leverage hovered slightly above 1.10, varying from 1.15 in the earliest recorded quarter to 1.10 in the latest. This indicates a stable use of total assets relative to equity with minimal fluctuation. The slight downward trend implies gradual de-leveraging or equity growth outpacing asset increases.
Overall, the company exhibits a conservative financial structure, characterized by very low debt levels and stable financial leverage. The absence of recorded debt data beyond 2017 might imply either a negligible debt position or limited disclosures in those periods. The financial leverage ratio's stability suggests consistent management of assets and equity without significant changes in financial risk exposure.
Debt Ratios
Debt to Equity
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Current portion of capital lease obligation | |||||||||||||||||||||||||||||
| Capital lease obligation, net of current portion | |||||||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).
1 Q2 2023 Calculation
            Debt to equity = Total debt ÷ Stockholders’ equity
            =  ÷  = 
2 Click competitor name to see calculations.
The financial data indicates a limited presence of total debt, with values reported only for the first two quarters of 2017, standing at approximately $16.15 million and $15.96 million respectively, after which no further debt amounts are recorded. This suggests either full repayment or reclassification of debt subsequent to September 2017.
Stockholders' equity demonstrates a consistent upward trend throughout the entire period from June 2017 to September 2022. Starting at approximately $567 million in mid-2017, the equity base expands steadily, exceeding $1.5 billion by the third quarter of 2022. This growth reflects sustained equity accumulation, possibly driven by retained earnings, capital injections, or valuation increases in assets.
The debt to equity ratio is available only for the first two quarters of the period and remains very low at 0.03. This low leverage ratio, combined with the absence of subsequent debt, indicates a strong equity position relative to debt, highlighting a conservative capital structure during this timeframe.
Overall, the financial trends suggest a solid and growing equity foundation with minimal reliance on debt financing. The stable and increasing equity levels denote financial strength and potential capacity for future investments funded through equity or internally generated funds.
Debt to Capital
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Current portion of capital lease obligation | |||||||||||||||||||||||||||||
| Capital lease obligation, net of current portion | |||||||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).
1 Q2 2023 Calculation
            Debt to capital = Total debt ÷ Total capital
            =  ÷  = 
2 Click competitor name to see calculations.
- Total Debt
- The total debt figures are only available for the first two quarters, showing a slight decrease from 16,154 thousand US dollars on June 30, 2017, to 15,961 thousand US dollars on September 30, 2017. After these periods, no debt data is reported, which could indicate either the absence of debt or missing disclosure in subsequent quarters.
- Total Capital
- Total capital demonstrates a consistent upward trend from June 30, 2017, through September 30, 2022. Starting at 583,198 thousand US dollars, capital increases steadily over time, reaching 1,539,787 thousand US dollars by the last reported quarter. This growth suggests an ongoing expansion of the company's capital base over the observed period.
- Debt to Capital Ratio
- The debt to capital ratio is only reported for the first two quarters in 2017, remaining constant at 0.03. Given the absence of debt data and ratio figures for the remaining periods, it is not possible to assess how leverage evolved during the subsequent quarters. The initial low ratio indicates modest leverage relative to the capital base at that time.
Debt to Assets
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Current portion of capital lease obligation | |||||||||||||||||||||||||||||
| Capital lease obligation, net of current portion | |||||||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).
1 Q2 2023 Calculation
            Debt to assets = Total debt ÷ Total assets
            =  ÷  = 
2 Click competitor name to see calculations.
The financial data reveals several key trends in the company's balance sheet items over the examined quarterly periods.
- Total Debt
- The total debt reported was approximately $16.2 million and $16.0 million in the first two quarters of the data presented (mid-2017). Subsequent quarters show no recorded debt values, indicating either full repayment, reclassification, or absence of new debt issuance during the remaining periods.
- Total Assets
- Total assets exhibited a consistent upward trajectory throughout the entire period analyzed, increasing from roughly $652 million in June 2017 to about $1.70 billion by September 2022. The growth was steady with no notable declines, suggesting ongoing asset accumulation, likely driven by investments, retained earnings, or operational expansion.
- Debt to Assets Ratio
- The ratio was steady at 0.02 for the two initial quarters reported, aligning with the presence of total debt and asset levels at that time. Absence of further ratio data correlates with the lack of reported debt, indicating a minimal or negligible debt burden relative to assets in later periods.
Overall, the company's financial position appears to have strengthened through substantial asset growth across multiple years while maintaining a very low debt level. This suggests a conservative capital structure with possible reliance on equity or internal financing, thus reducing financial risk associated with leverage. The continuous asset buildup likely supports expanded operational capacity or strategic investments.
Financial Leverage
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30).
1 Q2 2023 Calculation
            Financial leverage = Total assets ÷ Stockholders’ equity
            =  ÷  = 
2 Click competitor name to see calculations.
- Total Assets
- 
    The total assets demonstrate a consistent upward trend throughout the periods analyzed. Starting at approximately 652 million US dollars in mid-2017, the assets increased steadily to reach over 1.7 billion US dollars by late 2022. This growth reflects ongoing expansion and accumulation of resources over the nearly five-year timeframe, with no significant declines or volatility observed. 
- Stockholders’ Equity
- 
    Stockholders' equity also exhibits a persistent increase over the examined quarters, beginning at around 567 million US dollars in June 2017 and rising to approximately 1.54 billion US dollars by September 2022. While the growth is fairly consistent, some minor fluctuations appear, such as a slight dip in the third quarter of 2019 and again in early 2021, but the general trajectory remains positive, indicating strengthened equity base and retained earnings accumulation over time. 
- Financial Leverage
- 
    The financial leverage ratio remains relatively stable throughout the period, fluctuating narrowly between 1.10 and 1.15. This narrow range suggests a conservative and steady approach to the company’s capital structure, with a slight gradual decrease in leverage evident towards the end of the timeframe. Maintaining leverage close to 1.1 implies limited reliance on debt financing relative to equity, supporting a stable financial risk profile. 
- Overall Assessment
- 
    The company shows robust asset growth accompanied by a proportional increase in stockholders’ equity, suggesting effective management of resources and retained earnings. The steady and low leverage ratio corroborates a cautious financing strategy, focusing more on equity than on debt. No abrupt changes or financial stresses are visible in the reviewed data, reflecting a stable financial condition and a consistent expansion pattern.